stockrowVaxcyte, Inc.
PCVX Healthcare Biotechnology
- EPS
- −61.5%
- Free cash flow
- −92.6%
Quarter to June 2026, against a year earlier
Follow PCVX
Alert me
Vaxcyte, Inc. (PCVX) Free cash flow
Vaxcyte, Inc.'s free cash flow for fiscal 2025 was −$669.3M, compared with −$475.1M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$894.1M. Over the past ten years it has ranged from −$669.3M (fiscal 2025) to −$32.2M (fiscal 2018) — the current reading is the lowest in ten years. Free cash flow has fallen for 5 consecutive fiscal years. Vaxcyte, Inc. ranks 600th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$669.3M | — |
| FY2024 | −$475.1M | — |
| FY2023 | −$312.9M | — |
| FY2022 | −$176.4M | — |
| FY2021 | −$127.9M | — |
| FY2020 | −$47.7M | — |
| FY2019 | −$48.3M | — |
| FY2018 | −$32.2M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | −$236.8M | — |
| Mar 2026 | −$282.7M | — |
| Dec 2025 | −$227.5M | — |
| Sep 2025 | −$147.1M | — |
| 26 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| BMRN BioMarin Pharmaceutical Inc. compare | $557.9M |
| TECH Bio-Techne Corp compare | $263.2M |
| PTGX Protagonist Therapeutics, Inc. compare | $130.6M |
| CAI Caris Life Sciences,�Inc. compare | $83.9M |
| TGTX TG Therapeutics, Inc. compare | $17.4M |
| TWST Twist Bioscience Corporation compare | −$95.6M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$168.7M |
| IBRX ImmunityBio, Inc. compare | −$288.1M |
| PCVX Vaxcyte, Inc. | −$894.1M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)